Clinical Proteomics -a new perspective on old diseases

Clinical and translational proteomics are often aimed at better understanding cellular and molecular make-up of the disease. It can be done by identification of the unique presence, absent or abnormal levels of disease-associated proteins and peptides in the relevant tissues or biofluids. Proteomics aims also to detect disease-related posttranslational modifications and aberrant cellular localization. The introduction of modern technologies into the field of proteomics, facilitates the rapid and relatively inexpensive implementation of better and earlier diagnosis, personalized treatment options, precision medicine and advanced big-data-dependent patient care. The proteins and peptides associated with diseases can be extremely rare in the body fluids or tissues, and tissues samples available for the proteomics analysis can be small as needle biopsies or a section from paraffin blocks.

In this study we will present few examples utilizing different solutions to those limitations, including proteome from paraffin sections, specific protein enrichment, peptides identification from body fluids and the proteome of extracellular vesicles found in body specific to the disease from plasma or urine. We will focus on amyloidosis, cancer and neurodegenerative diseases.